The FDA’s Orphan Drug Designation is aimed at advancing treatments for rare diseases, including Acute Radiation Syndrome (ARS), which currently has limited treatment options. NeoImmuneTech’s NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS….